
    
      This is a Phase 1b/2, multicenter, open-label, study of MEDI-551 in combination with
      immunomodulating therapy evaluating the safety, tolerability, pharmacokinetics,
      immunogenicity and anti-tumor activity in subjects with relapsed or refractory aggressive
      B-cell lymphomas
    
  